SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing intense community speculation and high volatility as investors anticipate the imminent 80th event milestone for the REGAL Phase 3 trial. Discussion is heavily focused on the stock's elevated short interest and rising borrow rates, with bulls positioning for a potential squeeze while highlighting the company's recent commentary on its transition toward late-stage commercialization.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to advance solid-state battery development and manufacturing processes. Community sentiment is currently split between optimism regarding this high-profile validation of the company's technology and skepticism over the lack of near-term commercial revenue.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is seeing intense trading volume and volatility as the market reacts to shifting geopolitical tensions between the U.S. and Iran alongside broader uncertainty regarding Federal Reserve rate policy. Community discussions remain polarized, with many traders actively debating the sustainability of the ongoing AI-driven rally while utilizing the ETF to capitalize on rapid intraday price swings.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending following a record-breaking earnings report that highlighted significant revenue growth and the company's first positive operating cash flow, fueling investor excitement. The community is buzzing over the success of their AI-powered ultrasound technology and the strategic scalability of their partnership-driven business model, leading to discussions about the stock's potential for further upward momentum.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is facing extreme selling pressure and high short interest, with community discourse centered on whether the stock is a deep-value opportunity or a failing asset amid concerns over debt and subscriber losses. Investors are closely monitoring significant insider share purchases and potential merger catalysts as the primary drivers that could trigger a reversal from its recent lows.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as investors react to the official announcement that pre-orders for Grand Theft Auto VI will open on June 25, fueling significant bullish sentiment around the game's commercial impact. The community is actively discussing the potential for record-breaking sales, the stock's long-term valuation as an entertainment ecosystem, and its recent technical breakout above the 200-day moving average.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus Energy is trending as investors weigh a major joint venture with Oklo against recent price volatility, while the community remains focused on the stock's critical role as the primary domestic supplier of HALEU for the expanding U.S. nuclear energy sector. Discussion is currently dominated by debates over whether recent pullbacks represent an institutional shakeout of weak hands or a necessary valuation adjustment ahead of long-term infrastructure scaling.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing a sharp surge in momentum and heavy volume as investors price in potential regulatory milestones for peptide weight-loss treatments and a favorable analyst price target revision. The community is actively debating the stock's potential for a short squeeze, with many focusing on institutional accumulation and the company's aggressive expansion strategy.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors debate the sustainability of the current AI-driven market rally amid ongoing geopolitical instability and concerns over high tech valuations. Community discussion remains polarized, with many retail traders highlighting frustrations over market manipulation and the inherent risks of holding leveraged inverse products during an extended uptrend.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is under pressure as markets navigate conflicting headlines regarding a potential U.S.-Iran peace deal and the status of the Strait of Hormuz blockade. While community discussions are dominated by debates over supply deficits, tank-bottom inventories, and the impact of geopolitical risk premiums on energy stocks, traders remain sharply divided on whether current price action reflects genuine fundamental shifts or tactical market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Nyxoah Stock Tuesday?

Nyxoah (NYXH) raises $95M via public offering to fund U.S. commercial growth and Genio system R&D. Stock ticks up in premarket.read more...

FDA Milestones Fueling Expansion

The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH

Why Is NYXH Stock Falling Today?

Equity

The company priced its stock offering on Friday at a steep discount, with proceeds to be used to expand commercialization activities in the United States.


Nyxoah SA (NYXH) Reports Q1 Loss, Tops Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of +19.88% and +4.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates

Evolent Health (EVH) delivered earnings and revenue surprises of +57.17% and -6.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah (NYXH) Projected to Post Earnings on Tuesday

Nyxoah (NASDAQ:NYXH) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-nyxoah-sa-stock...

Nyxoah SA (NYXH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare (THC) Q1 Earnings Top Estimates

Tenet (THC) delivered earnings and revenue surprises of +14.39% and -0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Nyxoah (NASDAQ:NYXH) Price Target Lowered to $8.00 at Stifel Nicolaus

Stifel Nicolaus reduced their price target on shares of Nyxoah from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday...

Nyxoah SA (NASDAQ:NYXH) Receives Consensus Rating of "Moderate Buy" from Brokerages

Nyxoah SA (NASDAQ:NYXH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has...

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah SA

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.60
Prev Close	$1.59
Open	$1.64
Dividend Yield	0.00%
50-Day Moving Average	$2.71
Beta	1.12
Avg. Volume	42,143.51
PE Ratio	-0.65

52-Week High	$8.59
52-Week Low	$1.26
Market Capitalization	$159.88M
EPS (Annual)	-$2.67
Price to Book	1.69
Revenue Per Employee	N/A

NYXHNyxoah SA

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NYXH News